{"gene":"TMPRSS2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2020,"finding":"SARS-CoV-2 uses ACE2 as its entry receptor and TMPRSS2 as the host serine protease required for priming (proteolytic activation) of the viral spike protein, enabling membrane fusion and cell entry; a clinically approved TMPRSS2 inhibitor (camostat) blocked this entry.","method":"Pseudovirus entry assays, live virus infection of cell lines with and without TMPRSS2 expression, pharmacological inhibition with camostat mesylate","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — foundational study with multiple orthogonal methods, widely replicated across many independent labs","pmids":["32142651"],"is_preprint":false},{"year":2005,"finding":"Recurrent chromosomal rearrangements fuse the 5' UTR/promoter of the androgen-regulated TMPRSS2 gene to ETS transcription factor coding sequences (ERG, ETV1), placing ETS oncogene expression under androgen-responsive TMPRSS2 promoter control in prostate cancer.","method":"Bioinformatics outlier expression analysis, RT-PCR, FISH on prostate cancer tissue samples, cell line experiments demonstrating androgen-responsive promoter driving ETS expression","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery, replicated extensively across many independent cohorts and labs","pmids":["16254181"],"is_preprint":false},{"year":1999,"finding":"TMPRSS2 is a transmembrane serine protease with androgen-regulated expression predominantly in prostate epithelium; its gene is located on chromosome 21 and encodes domains including a transmembrane region and serine protease domain, placing it on the cell surface.","method":"cDNA microarray profiling of androgen-treated prostate cancer cells, Northern analysis, in situ hybridization of normal and malignant prostate tissues","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple complementary methods, foundational characterization replicated by subsequent studies","pmids":["10485450"],"is_preprint":false},{"year":2008,"finding":"The TMPRSS2-ERG gene fusion product drives invasion of prostate epithelial cells by engaging the plasminogen activation pathway, and ERG knockdown in TMPRSS2-ERG-positive VCaP cells inhibits invasion and induces a prostate differentiation transcriptional program.","method":"Transgenic mouse model (ERG under androgen-regulated promoter), introduction of ERG fusion into primary/immortalized prostate epithelial cells, ERG siRNA knockdown in VCaP cells, transcriptional profiling, invasion assays","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo mouse model and in vitro functional assays","pmids":["18283340"],"is_preprint":false},{"year":2022,"finding":"The crystal structure of TMPRSS2 (1.95 Å) co-crystallized with nafamostat reveals the substrate binding pocket architecture; TMPRSS2 cleaves SARS-CoV-2 spike protein at multiple sites including the canonical S1/S2 cleavage site, and inhibitor potency was ranked using in vitro protease activity assays.","method":"Recombinant protein production, X-ray crystallography, in vitro protease activity assays, inhibitor IC50 determination","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation by in vitro enzymatic assays and inhibitor characterization","pmids":["35676539"],"is_preprint":false},{"year":2022,"finding":"SARS-CoV-2 Omicron spike is less efficiently cleaved at S1/S2 compared to Delta, leading to reduced use of the TMPRSS2-dependent plasma membrane fusion pathway and greater reliance on the endocytic/cathepsin pathway; deletion of TMPRSS2 impaired Delta entry more than Omicron entry, explaining altered cell tropism.","method":"Spike-pseudotyped virus entry assays in cell lines with differential TMPRSS2 expression, TMPRSS2 gene deletion, drug inhibitors targeting specific entry pathways, syncytium formation assays, viral replication in human airway organoids","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, mechanistic dissection of protease pathway usage","pmids":["35104837"],"is_preprint":false},{"year":2018,"finding":"The TMPRSS2-ERG fusion protein (ERG) interacts with mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complexes; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA motif-dependent manner, and requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation.","method":"Co-immunoprecipitation, ChIP-seq, prostate organoid model with BAF complex perturbation, genome-wide chromatin occupancy mapping","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP, genome-wide ChIP-seq, functional organoid model","pmids":["30078722"],"is_preprint":false},{"year":2021,"finding":"TMPRSS2 is identified as a direct substrate/binding partner of HAI-2 (hepatocyte growth factor activator inhibitor-2), which co-immunoprecipitates with and inhibits TMPRSS2 proteolytic activity; HAI-2 suppresses TMPRSS2-mediated pro-HGF activation, extracellular matrix degradation, and prostate cancer cell invasion and metastasis.","method":"Co-immunoprecipitation, LC/MS/MS, recombinant protein binding and inhibition assays, immunofluorescence colocalization, in vitro invasion assays, orthotopic xenograft mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP with MS identification, biochemical inhibition assays, and in vivo validation","pmids":["32778768"],"is_preprint":false},{"year":2013,"finding":"Androgen regulation of TMPRSS2 requires an enhancer 13 kb upstream of the transcription start site containing an androgen response element (ARE) adjacent to two GATA2 binding sites; both the ARE and GATA2 sites contribute to enhancer activity, and a SNP (rs8134378) within the ARE reduces androgen receptor binding and transactivation.","method":"Bacterial artificial chromosome reporter assays, DNase I footprinting to identify GATA2 binding sites, ARE mutagenesis, androgen receptor binding assays, SNP functional analysis","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple methods including footprinting, BAC reporters, mutagenesis, and binding assays","pmids":["24109594"],"is_preprint":false},{"year":2021,"finding":"Alpha-1 antitrypsin (α1AT), a serine protease inhibitor abundant in the respiratory tract, binds and inactivates TMPRSS2, thereby inhibiting SARS-CoV-2 spike-mediated entry and viral replication in cell lines and primary human airway epithelial cultures.","method":"Bronchoalveolar lavage peptide/protein library screen, enzyme activity assays demonstrating α1AT inhibition of TMPRSS2, pseudovirus and authentic SARS-CoV-2 infection assays, primary human airway epithelial cultures","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical binding and inhibition assays combined with functional viral entry assays in multiple cell models","pmids":["33741941"],"is_preprint":false},{"year":2017,"finding":"Clinical isolates of human coronaviruses HCoV-OC43 and HCoV-HKU1 preferentially use cell-surface TMPRSS2 for spike protein priming and cell entry rather than endosomal cathepsins; cell-culture-adapted HCoV-OC43 lost ability to infect human bronchial tracheal epithelial air-liquid interface cultures.","method":"Viral infection assays with clinical isolates vs. cell-culture-adapted strains, pharmacological inhibition of TMPRSS2 vs. cathepsins, air-liquid interface culture infection","journal":"Virology","confidence":"High","confidence_rationale":"Tier 2 — multiple viral strains and inhibitor approaches, functional entry pathway determination","pmids":["29217279"],"is_preprint":false},{"year":2023,"finding":"TMPRSS2 functions as a proteinaceous entry receptor for human coronavirus HKU1: TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and pseudovirus infection; catalytically inactive TMPRSS2 mutants still support pseudovirus entry despite lacking spike cleavage activity; TMPRSS2 binds HKU1 receptor binding domain with high affinity (Kd ~137–334 nM) but does not bind SARS-CoV-2.","method":"Pseudovirus infection assays, cell-cell fusion assays, catalytically inactive TMPRSS2 mutants, binding affinity measurements, nanobody inhibition of TMPRSS2-HKU1 interaction, authentic HKU1 virus infection of primary human bronchial cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis, binding assays, authentic virus, primary cell infection","pmids":["37879362"],"is_preprint":false},{"year":2024,"finding":"Crystal structure of the HKU1 receptor binding domain in complex with TMPRSS2 shows HKU1 recognizes residues lining the TMPRSS2 catalytic groove; positions 417 and 469 are determinants of HKU1 host tropism; structural basis of TMPRSS2 zymogen activation reveals autolytic conformational change that alters loops recognized by HKU1 and dramatically increases binding affinity.","method":"Crystal structure determination of HKU1-RBD:TMPRSS2 complex, zymogen and activated TMPRSS2 structures with nanobody, mutagenesis of interface residues, cross-species tropism analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with mutagenesis validation","pmids":["38964326"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of HKU1 spike bound to TMPRSS2 reveals that sialoglycan binding induces a conformational change in the NTD that promotes neighboring RBD opening for TMPRSS2 recognition, demonstrating synergistic glycan-protein receptor usage; the HKU1 RBD features an insertion subdomain engaging TMPRSS2 through three novel interfaces.","method":"Cryo-EM structure determination of HKU1 spike in inactive, glycan-activated, and TMPRSS2-anchored states, mutagenesis, binding assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures with mutagenesis and binding validation","pmids":["38964329"],"is_preprint":false},{"year":2021,"finding":"TMPRSS2 directly interacts with ACE2 (demonstrated by endogenous co-immunoprecipitation in human cells), and ACE2 is a TMPRSS2 substrate; camostat (a TMPRSS2 inhibitor) blocked cleavage of pseudotype SARS-CoV-2 spike without disrupting TMPRSS2-ACE2 interaction; androgen deprivation reduced both TMPRSS2 and ACE2 expression, attenuating SARS-CoV-2 spike-mediated cellular entry.","method":"Co-immunoprecipitation of endogenous TMPRSS2 and ACE2, substrate cleavage assay, pseudotype SARS-CoV-2 entry assay with camostat, androgen receptor antagonist treatment","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — endogenous Co-IP and functional assays in single study","pmids":["33681723"],"is_preprint":false},{"year":2022,"finding":"Furin and TMPRSS2 act synergistically in SARS-CoV-2 infectivity: the S2' fusion activation site (KPS815↓) was identified by proteomics and its cleavage enhanced by ACE2 engagement; ACE2 shedding by TMPRSS2 is required for TMPRSS2-mediated enhancement of cell-to-cell fusion in the absence of S1/S2 priming; the ACE2 collectrin dimerization domain is essential for the TMPRSS2 effect on fusion.","method":"Proteomics identification of S2' cleavage site, cell-to-cell fusion assays, pharmacological inhibitors of furin (BOS) and TMPRSS2 (camostat), ACE2 domain mutant constructs, authentic SARS-CoV-2 infection of Calu-3 cells","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1-2 — proteomics site identification, domain mutagenesis, authentic virus, multiple orthogonal methods","pmids":["35343766"],"is_preprint":false},{"year":2021,"finding":"TMPRSS2-mediated entry into lung cells is the dominant pathway for SARS-CoV-2, while hydroxychloroquine efficiently blocks cathepsin L-dependent endosomal entry but not TMPRSS2-dependent plasma membrane entry; SARS-CoV-2 is more dependent on TMPRSS2 than SARS-CoV-1, and this difference is determined by the furin cleavage site in the SARS-CoV-2 spike.","method":"Pseudovirus entry assays in cells with varying TMPRSS2 expression, pharmacological inhibition of cathepsin L vs. TMPRSS2, furin-cleavage site ablation and transfer mutagenesis between SARS-CoV-1 and -2 spikes","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic mutagenesis plus pharmacological dissection of entry pathways","pmids":["33465165"],"is_preprint":false},{"year":2022,"finding":"TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron replication in mouse airways in vivo; TMPRSS2-knockout mice show strongly reduced viral replication in nose, trachea, and lung for Beta variant and reduced Omicron spread despite Omicron preferring cathepsins in vitro.","method":"TMPRSS2-knockout C57BL/6 mice infected with SARS-CoV-2 Beta and Omicron variants, measurement of viral titers in respiratory tract tissues, weight loss monitoring","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic knockout with quantitative viral replication readouts, two variants tested","pmids":["36243815"],"is_preprint":false},{"year":2022,"finding":"A small-molecule compound N-0385 inhibits TMPRSS2 with low nanomolar potency and blocks SARS-CoV-2 infection in human lung cells and colonoids; in the K18-hACE2 transgenic mouse model, N-0385 provides prophylactic and therapeutic benefit, confirming TTSP-mediated spike proteolytic maturation is critical for SARS-CoV-2 infection in vivo.","method":"In vitro TMPRSS2 inhibition assays, Calu-3 and colonoid infection assays, K18-hACE2 transgenic mouse model prophylaxis and treatment experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assays combined with in vivo mouse model validation","pmids":["35344983"],"is_preprint":false},{"year":2015,"finding":"TMPRSS2 protease activity at the cell surface activates hepatitis C virus (HCV) infection at the post-binding/entry stage; TMPRSS2 wild-type but not catalytically inactive mutant enhances HCV susceptibility in Huh7 cells, and TMPRSS2 knockdown reduces infection.","method":"Stable TMPRSS2 wild-type and catalytic mutant expression in Huh7 cells, HCV infection assays, siRNA knockdown, cell-surface protease activity assays","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 1-2 — catalytic mutant, stable expression, knockdown with functional viral entry readout","pmids":["25203900"],"is_preprint":false},{"year":2015,"finding":"TMPRSS2 isoform 1 (with extended N-terminal cytoplasmic domain) is expressed in lung-derived cell lines and tissues, colocalizes with influenza hemagglutinin (HA), cleaves and activates HA, and activates SARS-CoV spike protein for cathepsin L-independent cell entry.","method":"RT-PCR for isoform expression, colocalization imaging, functional cleavage assays, pseudovirus entry assays with cathepsin inhibition","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays in single study characterizing a specific isoform","pmids":["26379044"],"is_preprint":false},{"year":2021,"finding":"EZH2 methylates ERG (the TMPRSS2-ERG fusion product) at lysine K362 within the internal auto-inhibitory domain; K362 methylation modifies intra-domain interactions, favors DNA binding, and enhances ERG transcriptional activity; AKT-phosphorylated EZH2 (pS21) favors ERG methylation downstream of PTEN loss; ERG and EZH2 interact and co-occupy genomic sites forming trans-activating complexes.","method":"In vitro methylation assays, mutagenesis of K362, ChIP-seq, Co-immunoprecipitation, genetically engineered mouse model (ERG/PTEN), mass spectrometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical methylation assay, mutagenesis, Co-IP, ChIP-seq, and in vivo mouse model","pmids":["34230470"],"is_preprint":false},{"year":2010,"finding":"Androgen treatment can induce the TMPRSS2:ERG chromosomal fusion in both malignant and non-malignant prostate epithelial cells, associated with androgen-induced spatial gene proximity of TMPRSS2 and ERG loci and expression of PIWIL1; this demonstrates fusions can arise prior to malignant transformation.","method":"RT-PCR detection of fusion transcripts after androgen treatment, FISH for gene proximity measurement, androgen receptor CAG repeat length analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — functional induction of fusion with mechanistic correlation to gene proximity, single study","pmids":["20947519"],"is_preprint":false},{"year":2017,"finding":"FOXO1 binds ERG (the TMPRSS2-ERG fusion product) and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases VCaP cell invasion in an ERG-dependent manner; concomitant ERG transgene expression and Foxo1 deletion in mouse prostate causes high-grade prostatic intraepithelial neoplasia.","method":"Co-immunoprecipitation of FOXO1 and ERG, transcriptional reporter assays, siRNA knockdown, invasion assays, genetically engineered mouse model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — Co-IP, functional assays, in vivo mouse genetic model","pmids":["28986382"],"is_preprint":false},{"year":2019,"finding":"Androgen receptor-activated enhancers E1 and E2 (located between PRCAT38 and TMPRSS2 on chromosome 21) form chromatin loops with both the PRCAT38 and TMPRSS2 promoters, co-regulating both genes; enhancer activity is mediated by AR/FOXA1 binding and acetyltransferase p300; knockout of E1 or E2 simultaneously reduced transcription of both genes and inhibited cell growth and migration.","method":"Chromatin looping assays (3C/ChIA-PET), enhancer knockout (CRISPR), ChIP for AR, FOXA1, and p300, cell growth and migration assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — chromatin looping with CRISPR knockout validation, single study","pmids":["31405024"],"is_preprint":false},{"year":2022,"finding":"A common TMPRSS2 variant rs12329760 (p.V160M) reduces TMPRSS2 catalytic activity and is less able to support SARS-CoV-2 spike-mediated entry into cells; homozygous carriers have significantly decreased risk of severe COVID-19.","method":"SARS-CoV-2 pseudovirus entry assay in HEK293 cells co-transfected with ACE2 and wild-type or V160M TMPRSS2, epidemiological association in 2,244 ICU patients","journal":"Current research in translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vitro assay with clinical genetic association, single study","pmids":["35104687"],"is_preprint":false},{"year":2022,"finding":"An RNA G-quadruplex (RG4) structure within TMPRSS2 mRNA inhibits TMPRSS2 translation; G4-specific stabilizers attenuate SARS-CoV-2 infection in pseudovirus systems and mouse models; TMPRSS2 protein is increased in COVID-19 patient lungs.","method":"Bioinformatics identification of RG4, biochemical and biophysical RG4 characterization, in vitro translation assays, pseudovirus infection, mouse model with G4 stabilizers, COVID-19 patient lung protein analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical RG4 characterization plus functional translation and infection assays, in vivo validation","pmids":["35301316"],"is_preprint":false},{"year":2022,"finding":"Antithrombin (AT), an endogenous serine protease inhibitor, binds and inhibits TMPRSS2 (demonstrated by molecular docking and enzyme activity assays), blocking spike-mediated entry of multiple coronaviruses and suppressing authentic SARS-CoV-2 lung cell infection; heparin/fondaparinux activation of AT increases its anti-TMPRSS2 activity.","method":"Molecular docking, enzyme activity assays, pseudovirus entry assays for multiple coronavirus spikes, authentic SARS-CoV-2 lung cell infection assay","journal":"Journal of medical virology","confidence":"Medium","confidence_rationale":"Tier 2 — enzyme activity assays combined with functional viral entry assays, single study","pmids":["36056630"],"is_preprint":false},{"year":2020,"finding":"miR-98-5p directly targets TMPRSS2 mRNA and was mechanistically validated as a regulator of TMPRSS2 protein expression in human lung and umbilical vein endothelial cells.","method":"Bioinformatic miRNA target prediction, functional validation of miR-98-5p regulation of TMPRSS2 in two human endothelial cell lines","journal":"Biomedicines","confidence":"Low","confidence_rationale":"Tier 3 — single study, functional validation not extensively detailed in abstract","pmids":["33143053"],"is_preprint":false},{"year":2021,"finding":"Androgens regulate TMPRSS2 expression in lung epithelial cells via androgen receptor; antiandrogen enzalutamide reduces TMPRSS2 levels in human lung cells and mouse lung, significantly reducing SARS-CoV-2 entry and infection.","method":"Quantitative gene expression analysis in lung cell lines and mouse lung, antiandrogen treatment, SARS-CoV-2 infection assays in lung cells with and without enzalutamide","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct AR-TMPRSS2 transcriptional link shown with functional viral entry consequence, single study","pmids":["34210968"],"is_preprint":false},{"year":2023,"finding":"PM2.5 activates AhR, which translocates to the nucleus and directly binds the TMPRSS2 promoter, upregulating TMPRSS2 and downstream IL18 expression to promote lung cancer progression; TMPRSS2 depletion suppressed anchorage-independent growth and xenograft tumor growth.","method":"AhR nuclear translocation assays, ChIP showing AhR binding to TMPRSS2 promoter, TMPRSS2 knockdown in lung cancer cells, anchorage-independent growth assays, xenograft mouse model","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP evidence for direct AhR-TMPRSS2 promoter interaction with functional KD validation in vivo","pmids":["36975376"],"is_preprint":false},{"year":2013,"finding":"TMPRSS2/ERG gene fusion is expressed in prostate cancer stem cells with monoallelic regulation; TMPRSS2 transcription is subject to tight monoallelic control throughout the prostate epithelial hierarchy in both normal and tumor tissues, relaxed during differentiation.","method":"FISH for fusion gene in sorted prostate cancer stem cells, allele-specific expression analysis, single cell clonal analysis of asymmetric division","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — allele-specific expression and stem cell sorting with functional characterization, single study","pmids":["23535644"],"is_preprint":false}],"current_model":"TMPRSS2 is a type II transmembrane serine protease that is autocatalytically activated from its zymogen form and functions at the cell surface to proteolytically prime viral spike proteins (including SARS-CoV-2, influenza hemagglutinin, and HCoV-HKU1) for membrane fusion and viral entry; in prostate cancer, its androgen-regulated promoter is recurrently fused to ETS oncogene coding sequences (most commonly ERG), driving androgen-dependent ETS overexpression and invasion, while the TMPRSS2-ERG fusion protein recruits BAF chromatin remodeling complexes and is post-translationally regulated by EZH2-mediated methylation at K362, with endogenous inhibitors including HAI-2, alpha-1 antitrypsin, and antithrombin modulating its proteolytic activity."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing TMPRSS2 as a novel transmembrane serine protease with androgen-regulated expression in prostate epithelium defined the gene's identity, domain architecture, and hormonal control before any functional role was known.","evidence":"cDNA microarray of androgen-treated prostate cancer cells, Northern blot, in situ hybridization","pmids":["10485450"],"confidence":"High","gaps":["No endogenous substrate identified","Catalytic activity not directly demonstrated","Expression in non-prostate tissues not systematically surveyed"]},{"year":2005,"claim":"Discovery that recurrent TMPRSS2-ETS gene fusions place oncogenic ETS transcription factors under androgen-responsive TMPRSS2 promoter control established a new paradigm for epithelial cancer-associated gene fusions and explained the frequent ETS overexpression in prostate cancer.","evidence":"Outlier expression bioinformatics, RT-PCR, FISH on prostate cancer tissues","pmids":["16254181"],"confidence":"High","gaps":["Mechanism by which fusion drives transformation not yet defined","Frequency across ethnic groups unknown","Cooperating oncogenic events not identified"]},{"year":2008,"claim":"Demonstrating that the TMPRSS2-ERG fusion product drives prostate epithelial cell invasion through the plasminogen activation pathway resolved how ETS overexpression contributes to prostate cancer aggressiveness.","evidence":"Transgenic mouse model, ERG knockdown in VCaP cells, invasion assays, transcriptional profiling","pmids":["18283340"],"confidence":"High","gaps":["Whether ERG suffices for full transformation or requires cooperating events","Direct ERG transcriptional targets mediating invasion incompletely mapped"]},{"year":2010,"claim":"Showing that androgen treatment can induce TMPRSS2-ERG chromosomal fusions in non-malignant prostate cells addressed whether the fusion is an initiating event or consequence of malignancy, establishing that androgen-driven spatial proximity of the TMPRSS2 and ERG loci enables rearrangement prior to transformation.","evidence":"RT-PCR for fusion transcripts after androgen treatment, FISH for gene proximity","pmids":["20947519"],"confidence":"Medium","gaps":["Frequency of de novo fusion induction in normal cells very low","DNA repair defect requirement not tested","Not independently replicated"]},{"year":2013,"claim":"Identification of the upstream androgen-responsive enhancer with ARE and GATA2 sites, plus a functional SNP (rs8134378) modulating AR binding, provided the cis-regulatory architecture explaining how androgens control TMPRSS2 transcription and how genetic variation affects expression levels.","evidence":"BAC reporters, DNase I footprinting, ARE mutagenesis, AR binding assays, SNP functional analysis","pmids":["24109594"],"confidence":"High","gaps":["Contribution of additional distal enhancers not fully mapped","Tissue-specific enhancer usage (prostate vs. lung) not compared"]},{"year":2015,"claim":"Demonstrating that TMPRSS2 proteolytic activity at the cell surface activates HCV infection and cleaves influenza HA established TMPRSS2 as a broadly relevant host protease for respiratory and hepatotropic viruses beyond coronaviruses.","evidence":"Stable wild-type vs. catalytic mutant expression, HCV infection assays, HA cleavage assays, pseudovirus entry with cathepsin inhibition","pmids":["25203900","26379044"],"confidence":"High","gaps":["In vivo relevance for HCV not demonstrated","Full range of viral substrates not surveyed"]},{"year":2017,"claim":"Showing that clinical HCoV-OC43 and HCoV-HKU1 isolates preferentially use TMPRSS2 rather than cathepsins for spike priming established that the TMPRSS2-dependent plasma membrane entry route is the physiologically dominant pathway for human coronaviruses in airway epithelia.","evidence":"Infection assays with clinical vs. culture-adapted strains, pharmacological pathway dissection, air-liquid interface cultures","pmids":["29217279"],"confidence":"High","gaps":["Genetic knockout confirmation not performed","Whether other TTSPs can compensate not tested"]},{"year":2017,"claim":"Identification of FOXO1 as a direct binding partner and functional inhibitor of ERG activity, with in vivo validation that Foxo1 loss cooperates with ERG to drive prostate neoplasia, revealed a tumor-suppressive checkpoint on TMPRSS2-ERG oncogenic signaling.","evidence":"Co-IP, reporter assays, siRNA knockdown, invasion assays, genetically engineered mouse model","pmids":["28986382"],"confidence":"High","gaps":["How FOXO1-ERG interaction is regulated by upstream signals incompletely defined","Relevance in human prostate cancer progression not directly tested"]},{"year":2018,"claim":"Demonstrating that the TMPRSS2-ERG fusion protein directly recruits BAF (SWI/SNF) chromatin-remodeling complexes to ETS motifs genome-wide resolved the chromatin-level mechanism by which ERG overexpression reprograms the prostate cancer epigenome.","evidence":"Reciprocal Co-IP, ChIP-seq, prostate organoid model with BAF perturbation","pmids":["30078722"],"confidence":"High","gaps":["Which BAF subunit directly contacts ERG not identified","Whether BAF retargeting is reversible upon ERG depletion not shown"]},{"year":2020,"claim":"The landmark demonstration that SARS-CoV-2 requires TMPRSS2 for spike priming and cell entry—blockable by camostat—established TMPRSS2 as a therapeutic target for COVID-19 and explained the virus's tropism for TMPRSS2-expressing airway cells.","evidence":"Pseudovirus and authentic virus infection, TMPRSS2-expressing vs. non-expressing cells, camostat inhibition","pmids":["32142651"],"confidence":"High","gaps":["In vivo efficacy of camostat not yet demonstrated in this study","Relative contribution vs. cathepsin pathway in different tissues unknown"]},{"year":2021,"claim":"Identification of endogenous inhibitors alpha-1 antitrypsin and HAI-2 as direct TMPRSS2-binding inhibitors that suppress both viral entry and cancer cell invasion, respectively, revealed physiological regulatory mechanisms controlling TMPRSS2 proteolytic activity in airway and prostate contexts.","evidence":"Co-IP/MS for HAI-2, bronchoalveolar lavage screen for α1AT, enzyme activity assays, pseudovirus/authentic virus infection, xenograft models","pmids":["33741941","32778768"],"confidence":"High","gaps":["Whether α1AT deficiency predisposes to severe COVID-19 not causally demonstrated","Stoichiometry of HAI-2–TMPRSS2 complex not determined"]},{"year":2021,"claim":"Showing that EZH2 methylates the TMPRSS2-ERG fusion product at K362, enhancing ERG DNA binding and transcriptional activity downstream of PTEN loss/AKT signaling, integrated the TMPRSS2-ERG axis with PI3K and Polycomb pathways in prostate cancer progression.","evidence":"In vitro methylation assays, K362 mutagenesis, ChIP-seq, Co-IP, genetically engineered mouse model","pmids":["34230470"],"confidence":"High","gaps":["Whether K362 methylation is targetable therapeutically not tested","Dynamics of methylation during disease progression unknown"]},{"year":2022,"claim":"The crystal structure of TMPRSS2 with nafamostat revealed the substrate-binding pocket architecture and enabled structure-guided inhibitor optimization, while in vivo knockout and inhibitor studies (N-0385) confirmed TMPRSS2 is essential for SARS-CoV-2 replication in mouse airways across multiple variants including Omicron.","evidence":"X-ray crystallography at 1.95 Å, in vitro enzymatic assays, TMPRSS2-KO mice with Beta/Omicron infection, K18-hACE2 mouse model with N-0385","pmids":["35676539","36243815","35344983"],"confidence":"High","gaps":["No human clinical trial data for TMPRSS2-specific inhibitors","Whether compensatory proteases emerge under TMPRSS2 blockade in vivo not addressed"]},{"year":2022,"claim":"Demonstrating that SARS-CoV-2 Omicron shifts away from TMPRSS2-dependent plasma membrane entry toward cathepsin-dependent endosomal entry explained its altered cell tropism and reduced pathogenicity in the lower respiratory tract.","evidence":"Pseudovirus entry in cells with differential TMPRSS2, gene deletion, drug inhibitors, airway organoids","pmids":["35104837"],"confidence":"High","gaps":["Whether tropism shift is solely due to spike S1/S2 cleavage efficiency or involves other determinants","Long-term evolutionary trajectory of TMPRSS2 dependence unknown"]},{"year":2023,"claim":"The discovery that TMPRSS2 functions as a bona fide entry receptor for HCoV-HKU1—binding the viral RBD with high affinity even when catalytically dead—fundamentally expanded TMPRSS2's role from protease to receptor, revealing a dual protease-receptor function.","evidence":"Pseudovirus and authentic HKU1 infection, catalytic-dead TMPRSS2 mutants, Kd measurements, nanobody inhibition, primary bronchial cell infection","pmids":["37879362"],"confidence":"High","gaps":["Whether other TTSPs can substitute as HKU1 receptors not tested","Structural basis not yet resolved at this point"]},{"year":2024,"claim":"Crystal and cryo-EM structures of HKU1 RBD–TMPRSS2 complexes revealed that HKU1 recognizes the TMPRSS2 catalytic groove through an insertion subdomain, that zymogen-to-active conformational changes dramatically increase binding affinity, and that sialoglycan binding to HKU1 NTD allosterically promotes RBD opening for TMPRSS2 engagement—providing a complete structural model of synergistic dual-receptor usage.","evidence":"Crystal structures of HKU1-RBD:TMPRSS2 and zymogen/active TMPRSS2 with nanobody, cryo-EM of HKU1 spike in multiple states, mutagenesis, cross-species tropism analysis","pmids":["38964326","38964329"],"confidence":"High","gaps":["Whether therapeutic antibodies blocking the HKU1–TMPRSS2 interface are viable not tested","Structural basis for TMPRSS2's catalytic cleavage of HKU1 spike not resolved separately from receptor binding"]},{"year":null,"claim":"Key unresolved questions include the full endogenous substrate repertoire of TMPRSS2 in normal physiology, whether TMPRSS2 inhibition is clinically effective against respiratory viral infections in humans, and the structural determinants governing selectivity between TMPRSS2's protease versus receptor functions for different viruses.","evidence":"","pmids":[],"confidence":"Low","gaps":["No endogenous physiological substrate comprehensively validated in vivo","No completed human clinical trial demonstrating efficacy of TMPRSS2-specific inhibitors","Mechanism by which TMPRSS2 loss is tolerated in knockout mice (no overt phenotype) unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,4,5,15,16,19,20]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[11,12,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,0,19,11]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,3,6,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,5,16,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,29,30]}],"complexes":[],"partners":["ACE2","HAI-2","ERG","SERPINA1","FOXO1","EZH2","SMARCA4"],"other_free_text":[]},"mechanistic_narrative":"TMPRSS2 is a type II transmembrane serine protease, expressed under androgen receptor control predominantly in prostate and lung epithelia, that functions at the cell surface to proteolytically activate viral glycoproteins and endogenous substrates. Its serine protease domain cleaves the spike proteins of SARS-CoV-2, SARS-CoV, influenza hemagglutinin, and HCV entry factors, enabling plasma-membrane-route viral fusion; TMPRSS2 knockout in mice strongly reduces SARS-CoV-2 replication in the respiratory tract, and small-molecule inhibitors (camostat, nafamostat, N-0385) block this entry pathway [PMID:32142651, PMID:36243815, PMID:35344983]. Beyond its catalytic role, TMPRSS2 serves as a proteinaceous entry receptor for HCoV-HKU1, binding the viral RBD through its catalytic groove even when proteolytically inactive, with structural rearrangements upon zymogen activation dramatically increasing binding affinity [PMID:37879362, PMID:38964326]. In prostate cancer, recurrent chromosomal rearrangements fuse the androgen-responsive TMPRSS2 promoter to ETS family oncogenes (most commonly ERG), driving androgen-dependent ERG overexpression that recruits BAF chromatin-remodeling complexes genome-wide and promotes invasion through the plasminogen activation pathway [PMID:16254181, PMID:30078722, PMID:18283340]."},"prefetch_data":{"uniprot":{"accession":"O15393","full_name":"Transmembrane protease serine 2","aliases":["Serine protease 10"],"length_aa":492,"mass_kda":53.9,"function":"Plasma membrane-anchored serine protease that cleaves at arginine residues (PubMed:32703818, PubMed:35676539, PubMed:37990007, PubMed:38964328). Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate (PubMed:25122198). Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells (PubMed:15537383, PubMed:25122198, PubMed:26018085). In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia (By similarity) (Microbial infection) Facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via two independent mechanisms, proteolytic cleavage of ACE2 receptor which promotes viral uptake, and cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry (PubMed:24227843, PubMed:32142651, PubMed:32404436, PubMed:33051876, PubMed:34159616, PubMed:35676539, PubMed:37990007). The cleavage of SARS-COV2 spike glycoprotein occurs between the S2 and S2' site (PubMed:32703818). Upon SARS-CoV-2 infection, increases syncytia formation by accelerating the fusion process (PubMed:33051876, PubMed:34159616, PubMed:35676539). Proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity (Microbial infection) Receptor for human coronavirus HKU1-CoV, acts synergistically with disialoside glycans to facilitate the entry of the virus. After binding to cell-surface disialoside glycans, the viral S protein interacts with the inactive form of TMPRSS2 and inhibits its protease activity","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O15393/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TMPRSS2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TMPRSS2","total_profiled":1310},"omim":[{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"608067","title":"RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 2; RFWD2","url":"https://www.omim.org/entry/608067"},{"mim_id":"606565","title":"TRANSMEMBRANE PROTEASE, SERINE 4; TMPRSS4","url":"https://www.omim.org/entry/606565"},{"mim_id":"604503","title":"JUMONJI DOMAIN-CONTAINING PROTEIN 1C; JMJD1C","url":"https://www.omim.org/entry/604503"},{"mim_id":"602060","title":"TRANSMEMBRANE SERINE PROTEASE 2; TMPRSS2","url":"https://www.omim.org/entry/602060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":263.4},{"tissue":"stomach 1","ntpm":138.0}],"url":"https://www.proteinatlas.org/search/TMPRSS2"},"hgnc":{"alias_symbol":["PRSS10"],"prev_symbol":[]},"alphafold":{"accession":"O15393","domains":[{"cath_id":"3.10.250.10","chopping":"126-241","consensus_level":"high","plddt":91.6377,"start":126,"end":241},{"cath_id":"2.40.10.10","chopping":"248-492","consensus_level":"medium","plddt":88.5352,"start":248,"end":492}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15393","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15393-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15393-F1-predicted_aligned_error_v6.png","plddt_mean":79.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TMPRSS2","jax_strain_url":"https://www.jax.org/strain/search?query=TMPRSS2"},"sequence":{"accession":"O15393","fasta_url":"https://rest.uniprot.org/uniprotkb/O15393.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15393/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15393"}},"corpus_meta":[{"pmid":"32142651","id":"PMC_32142651","title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32142651","citation_count":14282,"is_preprint":false},{"pmid":"16254181","id":"PMC_16254181","title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16254181","citation_count":3117,"is_preprint":false},{"pmid":"35104837","id":"PMC_35104837","title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35104837","citation_count":842,"is_preprint":false},{"pmid":"32246845","id":"PMC_32246845","title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.","date":"2020","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/32246845","citation_count":818,"is_preprint":false},{"pmid":"18283340","id":"PMC_18283340","title":"Role of the TMPRSS2-ERG gene fusion in prostate cancer.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18283340","citation_count":561,"is_preprint":false},{"pmid":"10485450","id":"PMC_10485450","title":"Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10485450","citation_count":426,"is_preprint":false},{"pmid":"32276929","id":"PMC_32276929","title":"TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32276929","citation_count":291,"is_preprint":false},{"pmid":"32544566","id":"PMC_32544566","title":"ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection.","date":"2020","source":"The ocular surface","url":"https://pubmed.ncbi.nlm.nih.gov/32544566","citation_count":270,"is_preprint":false},{"pmid":"32422146","id":"PMC_32422146","title":"Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32422146","citation_count":264,"is_preprint":false},{"pmid":"17334343","id":"PMC_17334343","title":"Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17334343","citation_count":228,"is_preprint":false},{"pmid":"18172298","id":"PMC_18172298","title":"Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18172298","citation_count":211,"is_preprint":false},{"pmid":"33117379","id":"PMC_33117379","title":"ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117379","citation_count":210,"is_preprint":false},{"pmid":"28778717","id":"PMC_28778717","title":"TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.","date":"2017","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/28778717","citation_count":210,"is_preprint":false},{"pmid":"32861070","id":"PMC_32861070","title":"ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32861070","citation_count":187,"is_preprint":false},{"pmid":"33465165","id":"PMC_33465165","title":"Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/33465165","citation_count":176,"is_preprint":false},{"pmid":"35344983","id":"PMC_35344983","title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35344983","citation_count":170,"is_preprint":false},{"pmid":"29217279","id":"PMC_29217279","title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry.","date":"2017","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/29217279","citation_count":169,"is_preprint":false},{"pmid":"35676539","id":"PMC_35676539","title":"Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35676539","citation_count":158,"is_preprint":false},{"pmid":"33310900","id":"PMC_33310900","title":"Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33310900","citation_count":144,"is_preprint":false},{"pmid":"35343766","id":"PMC_35343766","title":"Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35343766","citation_count":140,"is_preprint":false},{"pmid":"11169526","id":"PMC_11169526","title":"Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11169526","citation_count":135,"is_preprint":false},{"pmid":"20118910","id":"PMC_20118910","title":"Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20118910","citation_count":130,"is_preprint":false},{"pmid":"33290397","id":"PMC_33290397","title":"Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.","date":"2020","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/33290397","citation_count":116,"is_preprint":false},{"pmid":"32469279","id":"PMC_32469279","title":"Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.","date":"2020","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/32469279","citation_count":116,"is_preprint":false},{"pmid":"33143053","id":"PMC_33143053","title":"miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33143053","citation_count":116,"is_preprint":false},{"pmid":"33741941","id":"PMC_33741941","title":"Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33741941","citation_count":112,"is_preprint":false},{"pmid":"24109594","id":"PMC_24109594","title":"Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24109594","citation_count":106,"is_preprint":false},{"pmid":"22245323","id":"PMC_22245323","title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.","date":"2012","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/22245323","citation_count":105,"is_preprint":false},{"pmid":"33180746","id":"PMC_33180746","title":"Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33180746","citation_count":101,"is_preprint":false},{"pmid":"24505269","id":"PMC_24505269","title":"TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24505269","citation_count":100,"is_preprint":false},{"pmid":"30078722","id":"PMC_30078722","title":"Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30078722","citation_count":86,"is_preprint":false},{"pmid":"21040948","id":"PMC_21040948","title":"TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.","date":"2010","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21040948","citation_count":85,"is_preprint":false},{"pmid":"35382133","id":"PMC_35382133","title":"Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.","date":"2020","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/35382133","citation_count":85,"is_preprint":false},{"pmid":"33707363","id":"PMC_33707363","title":"Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.","date":"2021","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33707363","citation_count":84,"is_preprint":false},{"pmid":"28849022","id":"PMC_28849022","title":"Significance of the TMPRSS2:ERG gene fusion in prostate cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849022","citation_count":84,"is_preprint":false},{"pmid":"20947519","id":"PMC_20947519","title":"Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20947519","citation_count":84,"is_preprint":false},{"pmid":"36243815","id":"PMC_36243815","title":"Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36243815","citation_count":82,"is_preprint":false},{"pmid":"32726325","id":"PMC_32726325","title":"Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32726325","citation_count":82,"is_preprint":false},{"pmid":"32873700","id":"PMC_32873700","title":"Gene of the month: TMPRSS2 (transmembrane serine protease 2).","date":"2020","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32873700","citation_count":81,"is_preprint":false},{"pmid":"37879362","id":"PMC_37879362","title":"TMPRSS2 is a functional receptor for human coronavirus HKU1.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37879362","citation_count":80,"is_preprint":false},{"pmid":"34045511","id":"PMC_34045511","title":"Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34045511","citation_count":80,"is_preprint":false},{"pmid":"32441816","id":"PMC_32441816","title":"Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32441816","citation_count":79,"is_preprint":false},{"pmid":"33681723","id":"PMC_33681723","title":"Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33681723","citation_count":79,"is_preprint":false},{"pmid":"33278516","id":"PMC_33278516","title":"ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.","date":"2020","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33278516","citation_count":76,"is_preprint":false},{"pmid":"32691890","id":"PMC_32691890","title":"ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.","date":"2020","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/32691890","citation_count":72,"is_preprint":false},{"pmid":"35301316","id":"PMC_35301316","title":"RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35301316","citation_count":67,"is_preprint":false},{"pmid":"36975376","id":"PMC_36975376","title":"PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36975376","citation_count":65,"is_preprint":false},{"pmid":"29844131","id":"PMC_29844131","title":"TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29844131","citation_count":63,"is_preprint":false},{"pmid":"34210968","id":"PMC_34210968","title":"The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34210968","citation_count":63,"is_preprint":false},{"pmid":"32703421","id":"PMC_32703421","title":"Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32703421","citation_count":58,"is_preprint":false},{"pmid":"35163273","id":"PMC_35163273","title":"The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163273","citation_count":57,"is_preprint":false},{"pmid":"28986382","id":"PMC_28986382","title":"Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28986382","citation_count":53,"is_preprint":false},{"pmid":"25263440","id":"PMC_25263440","title":"TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25263440","citation_count":52,"is_preprint":false},{"pmid":"36851486","id":"PMC_36851486","title":"TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection.","date":"2023","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36851486","citation_count":51,"is_preprint":false},{"pmid":"33853873","id":"PMC_33853873","title":"Term Human Placental Trophoblasts Express SARS-CoV-2 Entry Factors ACE2, TMPRSS2, and Furin.","date":"2021","source":"mSphere","url":"https://pubmed.ncbi.nlm.nih.gov/33853873","citation_count":49,"is_preprint":false},{"pmid":"33422505","id":"PMC_33422505","title":"Exposure to particulate matter upregulates ACE2 and TMPRSS2 expression in the murine lung.","date":"2021","source":"Environmental research","url":"https://pubmed.ncbi.nlm.nih.gov/33422505","citation_count":48,"is_preprint":false},{"pmid":"20800881","id":"PMC_20800881","title":"TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.","date":"2010","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/20800881","citation_count":45,"is_preprint":false},{"pmid":"23535644","id":"PMC_23535644","title":"Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23535644","citation_count":44,"is_preprint":false},{"pmid":"35104687","id":"PMC_35104687","title":"A common TMPRSS2 variant has a protective effect against severe COVID-19.","date":"2022","source":"Current research in translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35104687","citation_count":43,"is_preprint":false},{"pmid":"25203900","id":"PMC_25203900","title":"Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection.","date":"2015","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25203900","citation_count":43,"is_preprint":false},{"pmid":"34692233","id":"PMC_34692233","title":"Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/34692233","citation_count":41,"is_preprint":false},{"pmid":"34001248","id":"PMC_34001248","title":"Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients.","date":"2021","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34001248","citation_count":40,"is_preprint":false},{"pmid":"32778768","id":"PMC_32778768","title":"Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32778768","citation_count":40,"is_preprint":false},{"pmid":"33706759","id":"PMC_33706759","title":"Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19.","date":"2021","source":"Particle and fibre toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33706759","citation_count":39,"is_preprint":false},{"pmid":"33188579","id":"PMC_33188579","title":"Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.","date":"2021","source":"Stem cells translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33188579","citation_count":39,"is_preprint":false},{"pmid":"31405024","id":"PMC_31405024","title":"Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31405024","citation_count":37,"is_preprint":false},{"pmid":"34230470","id":"PMC_34230470","title":"EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34230470","citation_count":37,"is_preprint":false},{"pmid":"38964328","id":"PMC_38964328","title":"Human coronavirus HKU1 recognition of the TMPRSS2 host receptor.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964328","citation_count":34,"is_preprint":false},{"pmid":"33081421","id":"PMC_33081421","title":"Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/33081421","citation_count":34,"is_preprint":false},{"pmid":"26379044","id":"PMC_26379044","title":"TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26379044","citation_count":32,"is_preprint":false},{"pmid":"33108902","id":"PMC_33108902","title":"ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.","date":"2020","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/33108902","citation_count":32,"is_preprint":false},{"pmid":"34590312","id":"PMC_34590312","title":"ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium.","date":"2021","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/34590312","citation_count":31,"is_preprint":false},{"pmid":"21937078","id":"PMC_21937078","title":"The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.","date":"2011","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21937078","citation_count":31,"is_preprint":false},{"pmid":"34075330","id":"PMC_34075330","title":"A variant in TMPRSS2 is associated with decreased disease severity in COVID-19.","date":"2021","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/34075330","citation_count":30,"is_preprint":false},{"pmid":"27041928","id":"PMC_27041928","title":"PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.","date":"2016","source":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","url":"https://pubmed.ncbi.nlm.nih.gov/27041928","citation_count":29,"is_preprint":false},{"pmid":"38964329","id":"PMC_38964329","title":"TMPRSS2 and glycan receptors synergistically facilitate coronavirus entry.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964329","citation_count":28,"is_preprint":false},{"pmid":"35996506","id":"PMC_35996506","title":"ACE2 and TMPRSS2 SNPs as Determinants of Susceptibility to, and Severity of, a COVID-19 Infection.","date":"2022","source":"British journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/35996506","citation_count":26,"is_preprint":false},{"pmid":"33083800","id":"PMC_33083800","title":"Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33083800","citation_count":26,"is_preprint":false},{"pmid":"34284028","id":"PMC_34284028","title":"Computational analysis of TMPRSS2 expression in normal and SARS-CoV-2-infected human tissues.","date":"2021","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/34284028","citation_count":26,"is_preprint":false},{"pmid":"33609069","id":"PMC_33609069","title":"Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33609069","citation_count":26,"is_preprint":false},{"pmid":"32967703","id":"PMC_32967703","title":"TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32967703","citation_count":26,"is_preprint":false},{"pmid":"36795725","id":"PMC_36795725","title":"TMPRSS2 polymorphism (rs12329760) and the severity of the COVID-19 in Iranian population.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36795725","citation_count":25,"is_preprint":false},{"pmid":"34412632","id":"PMC_34412632","title":"Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34412632","citation_count":25,"is_preprint":false},{"pmid":"33638460","id":"PMC_33638460","title":"Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2.","date":"2021","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/33638460","citation_count":25,"is_preprint":false},{"pmid":"34995811","id":"PMC_34995811","title":"Genetic association of TMPRSS2 rs2070788 polymorphism with COVID-19 case fatality rate among Indian populations.","date":"2022","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34995811","citation_count":25,"is_preprint":false},{"pmid":"31614005","id":"PMC_31614005","title":"Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.","date":"2019","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/31614005","citation_count":25,"is_preprint":false},{"pmid":"35193695","id":"PMC_35193695","title":"Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.","date":"2022","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/35193695","citation_count":24,"is_preprint":false},{"pmid":"33660945","id":"PMC_33660945","title":"Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33660945","citation_count":24,"is_preprint":false},{"pmid":"33380375","id":"PMC_33380375","title":"Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?","date":"2020","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33380375","citation_count":23,"is_preprint":false},{"pmid":"21731703","id":"PMC_21731703","title":"Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21731703","citation_count":23,"is_preprint":false},{"pmid":"38964326","id":"PMC_38964326","title":"Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38964326","citation_count":21,"is_preprint":false},{"pmid":"35072549","id":"PMC_35072549","title":"The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.","date":"2022","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35072549","citation_count":21,"is_preprint":false},{"pmid":"36056630","id":"PMC_36056630","title":"Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.","date":"2022","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/36056630","citation_count":20,"is_preprint":false},{"pmid":"29167279","id":"PMC_29167279","title":"Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.","date":"2017","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29167279","citation_count":20,"is_preprint":false},{"pmid":"35000261","id":"PMC_35000261","title":"ACE2 and TMPRSS2 immunolocalization and oral manifestations of COVID-19.","date":"2022","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35000261","citation_count":19,"is_preprint":false},{"pmid":"35255100","id":"PMC_35255100","title":"Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35255100","citation_count":19,"is_preprint":false},{"pmid":"33421977","id":"PMC_33421977","title":"Genetic Susceptibility of ACE2 and TMPRSS2 in Six Common Cancers and Possible Impacts on COVID-19.","date":"2020","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33421977","citation_count":19,"is_preprint":false},{"pmid":"36146782","id":"PMC_36146782","title":"Association of the Transmembrane Serine Protease-2 (TMPRSS2) Polymorphisms with COVID-19.","date":"2022","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36146782","citation_count":19,"is_preprint":false},{"pmid":"35103351","id":"PMC_35103351","title":"Estradiol reduces ACE2 and TMPRSS2 mRNA levels in A549 human lung epithelial cells.","date":"2022","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/35103351","citation_count":18,"is_preprint":false},{"pmid":"35804152","id":"PMC_35804152","title":"Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35804152","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50203,"output_tokens":7717,"usd":0.133182},"stage2":{"model":"claude-opus-4-6","input_tokens":11435,"output_tokens":3925,"usd":0.23295},"total_usd":0.366132,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 uses ACE2 as its entry receptor and TMPRSS2 as the host serine protease required for priming (proteolytic activation) of the viral spike protein, enabling membrane fusion and cell entry; a clinically approved TMPRSS2 inhibitor (camostat) blocked this entry.\",\n      \"method\": \"Pseudovirus entry assays, live virus infection of cell lines with and without TMPRSS2 expression, pharmacological inhibition with camostat mesylate\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational study with multiple orthogonal methods, widely replicated across many independent labs\",\n      \"pmids\": [\"32142651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Recurrent chromosomal rearrangements fuse the 5' UTR/promoter of the androgen-regulated TMPRSS2 gene to ETS transcription factor coding sequences (ERG, ETV1), placing ETS oncogene expression under androgen-responsive TMPRSS2 promoter control in prostate cancer.\",\n      \"method\": \"Bioinformatics outlier expression analysis, RT-PCR, FISH on prostate cancer tissue samples, cell line experiments demonstrating androgen-responsive promoter driving ETS expression\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery, replicated extensively across many independent cohorts and labs\",\n      \"pmids\": [\"16254181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TMPRSS2 is a transmembrane serine protease with androgen-regulated expression predominantly in prostate epithelium; its gene is located on chromosome 21 and encodes domains including a transmembrane region and serine protease domain, placing it on the cell surface.\",\n      \"method\": \"cDNA microarray profiling of androgen-treated prostate cancer cells, Northern analysis, in situ hybridization of normal and malignant prostate tissues\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple complementary methods, foundational characterization replicated by subsequent studies\",\n      \"pmids\": [\"10485450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The TMPRSS2-ERG gene fusion product drives invasion of prostate epithelial cells by engaging the plasminogen activation pathway, and ERG knockdown in TMPRSS2-ERG-positive VCaP cells inhibits invasion and induces a prostate differentiation transcriptional program.\",\n      \"method\": \"Transgenic mouse model (ERG under androgen-regulated promoter), introduction of ERG fusion into primary/immortalized prostate epithelial cells, ERG siRNA knockdown in VCaP cells, transcriptional profiling, invasion assays\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo mouse model and in vitro functional assays\",\n      \"pmids\": [\"18283340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The crystal structure of TMPRSS2 (1.95 Å) co-crystallized with nafamostat reveals the substrate binding pocket architecture; TMPRSS2 cleaves SARS-CoV-2 spike protein at multiple sites including the canonical S1/S2 cleavage site, and inhibitor potency was ranked using in vitro protease activity assays.\",\n      \"method\": \"Recombinant protein production, X-ray crystallography, in vitro protease activity assays, inhibitor IC50 determination\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation by in vitro enzymatic assays and inhibitor characterization\",\n      \"pmids\": [\"35676539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 Omicron spike is less efficiently cleaved at S1/S2 compared to Delta, leading to reduced use of the TMPRSS2-dependent plasma membrane fusion pathway and greater reliance on the endocytic/cathepsin pathway; deletion of TMPRSS2 impaired Delta entry more than Omicron entry, explaining altered cell tropism.\",\n      \"method\": \"Spike-pseudotyped virus entry assays in cell lines with differential TMPRSS2 expression, TMPRSS2 gene deletion, drug inhibitors targeting specific entry pathways, syncytium formation assays, viral replication in human airway organoids\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, mechanistic dissection of protease pathway usage\",\n      \"pmids\": [\"35104837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The TMPRSS2-ERG fusion protein (ERG) interacts with mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complexes; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA motif-dependent manner, and requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, prostate organoid model with BAF complex perturbation, genome-wide chromatin occupancy mapping\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP, genome-wide ChIP-seq, functional organoid model\",\n      \"pmids\": [\"30078722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMPRSS2 is identified as a direct substrate/binding partner of HAI-2 (hepatocyte growth factor activator inhibitor-2), which co-immunoprecipitates with and inhibits TMPRSS2 proteolytic activity; HAI-2 suppresses TMPRSS2-mediated pro-HGF activation, extracellular matrix degradation, and prostate cancer cell invasion and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, LC/MS/MS, recombinant protein binding and inhibition assays, immunofluorescence colocalization, in vitro invasion assays, orthotopic xenograft mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP with MS identification, biochemical inhibition assays, and in vivo validation\",\n      \"pmids\": [\"32778768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Androgen regulation of TMPRSS2 requires an enhancer 13 kb upstream of the transcription start site containing an androgen response element (ARE) adjacent to two GATA2 binding sites; both the ARE and GATA2 sites contribute to enhancer activity, and a SNP (rs8134378) within the ARE reduces androgen receptor binding and transactivation.\",\n      \"method\": \"Bacterial artificial chromosome reporter assays, DNase I footprinting to identify GATA2 binding sites, ARE mutagenesis, androgen receptor binding assays, SNP functional analysis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple methods including footprinting, BAC reporters, mutagenesis, and binding assays\",\n      \"pmids\": [\"24109594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Alpha-1 antitrypsin (α1AT), a serine protease inhibitor abundant in the respiratory tract, binds and inactivates TMPRSS2, thereby inhibiting SARS-CoV-2 spike-mediated entry and viral replication in cell lines and primary human airway epithelial cultures.\",\n      \"method\": \"Bronchoalveolar lavage peptide/protein library screen, enzyme activity assays demonstrating α1AT inhibition of TMPRSS2, pseudovirus and authentic SARS-CoV-2 infection assays, primary human airway epithelial cultures\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical binding and inhibition assays combined with functional viral entry assays in multiple cell models\",\n      \"pmids\": [\"33741941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Clinical isolates of human coronaviruses HCoV-OC43 and HCoV-HKU1 preferentially use cell-surface TMPRSS2 for spike protein priming and cell entry rather than endosomal cathepsins; cell-culture-adapted HCoV-OC43 lost ability to infect human bronchial tracheal epithelial air-liquid interface cultures.\",\n      \"method\": \"Viral infection assays with clinical isolates vs. cell-culture-adapted strains, pharmacological inhibition of TMPRSS2 vs. cathepsins, air-liquid interface culture infection\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple viral strains and inhibitor approaches, functional entry pathway determination\",\n      \"pmids\": [\"29217279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TMPRSS2 functions as a proteinaceous entry receptor for human coronavirus HKU1: TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and pseudovirus infection; catalytically inactive TMPRSS2 mutants still support pseudovirus entry despite lacking spike cleavage activity; TMPRSS2 binds HKU1 receptor binding domain with high affinity (Kd ~137–334 nM) but does not bind SARS-CoV-2.\",\n      \"method\": \"Pseudovirus infection assays, cell-cell fusion assays, catalytically inactive TMPRSS2 mutants, binding affinity measurements, nanobody inhibition of TMPRSS2-HKU1 interaction, authentic HKU1 virus infection of primary human bronchial cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis, binding assays, authentic virus, primary cell infection\",\n      \"pmids\": [\"37879362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Crystal structure of the HKU1 receptor binding domain in complex with TMPRSS2 shows HKU1 recognizes residues lining the TMPRSS2 catalytic groove; positions 417 and 469 are determinants of HKU1 host tropism; structural basis of TMPRSS2 zymogen activation reveals autolytic conformational change that alters loops recognized by HKU1 and dramatically increases binding affinity.\",\n      \"method\": \"Crystal structure determination of HKU1-RBD:TMPRSS2 complex, zymogen and activated TMPRSS2 structures with nanobody, mutagenesis of interface residues, cross-species tropism analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with mutagenesis validation\",\n      \"pmids\": [\"38964326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of HKU1 spike bound to TMPRSS2 reveals that sialoglycan binding induces a conformational change in the NTD that promotes neighboring RBD opening for TMPRSS2 recognition, demonstrating synergistic glycan-protein receptor usage; the HKU1 RBD features an insertion subdomain engaging TMPRSS2 through three novel interfaces.\",\n      \"method\": \"Cryo-EM structure determination of HKU1 spike in inactive, glycan-activated, and TMPRSS2-anchored states, mutagenesis, binding assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with mutagenesis and binding validation\",\n      \"pmids\": [\"38964329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMPRSS2 directly interacts with ACE2 (demonstrated by endogenous co-immunoprecipitation in human cells), and ACE2 is a TMPRSS2 substrate; camostat (a TMPRSS2 inhibitor) blocked cleavage of pseudotype SARS-CoV-2 spike without disrupting TMPRSS2-ACE2 interaction; androgen deprivation reduced both TMPRSS2 and ACE2 expression, attenuating SARS-CoV-2 spike-mediated cellular entry.\",\n      \"method\": \"Co-immunoprecipitation of endogenous TMPRSS2 and ACE2, substrate cleavage assay, pseudotype SARS-CoV-2 entry assay with camostat, androgen receptor antagonist treatment\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — endogenous Co-IP and functional assays in single study\",\n      \"pmids\": [\"33681723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Furin and TMPRSS2 act synergistically in SARS-CoV-2 infectivity: the S2' fusion activation site (KPS815↓) was identified by proteomics and its cleavage enhanced by ACE2 engagement; ACE2 shedding by TMPRSS2 is required for TMPRSS2-mediated enhancement of cell-to-cell fusion in the absence of S1/S2 priming; the ACE2 collectrin dimerization domain is essential for the TMPRSS2 effect on fusion.\",\n      \"method\": \"Proteomics identification of S2' cleavage site, cell-to-cell fusion assays, pharmacological inhibitors of furin (BOS) and TMPRSS2 (camostat), ACE2 domain mutant constructs, authentic SARS-CoV-2 infection of Calu-3 cells\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — proteomics site identification, domain mutagenesis, authentic virus, multiple orthogonal methods\",\n      \"pmids\": [\"35343766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TMPRSS2-mediated entry into lung cells is the dominant pathway for SARS-CoV-2, while hydroxychloroquine efficiently blocks cathepsin L-dependent endosomal entry but not TMPRSS2-dependent plasma membrane entry; SARS-CoV-2 is more dependent on TMPRSS2 than SARS-CoV-1, and this difference is determined by the furin cleavage site in the SARS-CoV-2 spike.\",\n      \"method\": \"Pseudovirus entry assays in cells with varying TMPRSS2 expression, pharmacological inhibition of cathepsin L vs. TMPRSS2, furin-cleavage site ablation and transfer mutagenesis between SARS-CoV-1 and -2 spikes\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic mutagenesis plus pharmacological dissection of entry pathways\",\n      \"pmids\": [\"33465165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron replication in mouse airways in vivo; TMPRSS2-knockout mice show strongly reduced viral replication in nose, trachea, and lung for Beta variant and reduced Omicron spread despite Omicron preferring cathepsins in vitro.\",\n      \"method\": \"TMPRSS2-knockout C57BL/6 mice infected with SARS-CoV-2 Beta and Omicron variants, measurement of viral titers in respiratory tract tissues, weight loss monitoring\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockout with quantitative viral replication readouts, two variants tested\",\n      \"pmids\": [\"36243815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A small-molecule compound N-0385 inhibits TMPRSS2 with low nanomolar potency and blocks SARS-CoV-2 infection in human lung cells and colonoids; in the K18-hACE2 transgenic mouse model, N-0385 provides prophylactic and therapeutic benefit, confirming TTSP-mediated spike proteolytic maturation is critical for SARS-CoV-2 infection in vivo.\",\n      \"method\": \"In vitro TMPRSS2 inhibition assays, Calu-3 and colonoid infection assays, K18-hACE2 transgenic mouse model prophylaxis and treatment experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assays combined with in vivo mouse model validation\",\n      \"pmids\": [\"35344983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TMPRSS2 protease activity at the cell surface activates hepatitis C virus (HCV) infection at the post-binding/entry stage; TMPRSS2 wild-type but not catalytically inactive mutant enhances HCV susceptibility in Huh7 cells, and TMPRSS2 knockdown reduces infection.\",\n      \"method\": \"Stable TMPRSS2 wild-type and catalytic mutant expression in Huh7 cells, HCV infection assays, siRNA knockdown, cell-surface protease activity assays\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — catalytic mutant, stable expression, knockdown with functional viral entry readout\",\n      \"pmids\": [\"25203900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TMPRSS2 isoform 1 (with extended N-terminal cytoplasmic domain) is expressed in lung-derived cell lines and tissues, colocalizes with influenza hemagglutinin (HA), cleaves and activates HA, and activates SARS-CoV spike protein for cathepsin L-independent cell entry.\",\n      \"method\": \"RT-PCR for isoform expression, colocalization imaging, functional cleavage assays, pseudovirus entry assays with cathepsin inhibition\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays in single study characterizing a specific isoform\",\n      \"pmids\": [\"26379044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EZH2 methylates ERG (the TMPRSS2-ERG fusion product) at lysine K362 within the internal auto-inhibitory domain; K362 methylation modifies intra-domain interactions, favors DNA binding, and enhances ERG transcriptional activity; AKT-phosphorylated EZH2 (pS21) favors ERG methylation downstream of PTEN loss; ERG and EZH2 interact and co-occupy genomic sites forming trans-activating complexes.\",\n      \"method\": \"In vitro methylation assays, mutagenesis of K362, ChIP-seq, Co-immunoprecipitation, genetically engineered mouse model (ERG/PTEN), mass spectrometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical methylation assay, mutagenesis, Co-IP, ChIP-seq, and in vivo mouse model\",\n      \"pmids\": [\"34230470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Androgen treatment can induce the TMPRSS2:ERG chromosomal fusion in both malignant and non-malignant prostate epithelial cells, associated with androgen-induced spatial gene proximity of TMPRSS2 and ERG loci and expression of PIWIL1; this demonstrates fusions can arise prior to malignant transformation.\",\n      \"method\": \"RT-PCR detection of fusion transcripts after androgen treatment, FISH for gene proximity measurement, androgen receptor CAG repeat length analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional induction of fusion with mechanistic correlation to gene proximity, single study\",\n      \"pmids\": [\"20947519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXO1 binds ERG (the TMPRSS2-ERG fusion product) and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases VCaP cell invasion in an ERG-dependent manner; concomitant ERG transgene expression and Foxo1 deletion in mouse prostate causes high-grade prostatic intraepithelial neoplasia.\",\n      \"method\": \"Co-immunoprecipitation of FOXO1 and ERG, transcriptional reporter assays, siRNA knockdown, invasion assays, genetically engineered mouse model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, functional assays, in vivo mouse genetic model\",\n      \"pmids\": [\"28986382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Androgen receptor-activated enhancers E1 and E2 (located between PRCAT38 and TMPRSS2 on chromosome 21) form chromatin loops with both the PRCAT38 and TMPRSS2 promoters, co-regulating both genes; enhancer activity is mediated by AR/FOXA1 binding and acetyltransferase p300; knockout of E1 or E2 simultaneously reduced transcription of both genes and inhibited cell growth and migration.\",\n      \"method\": \"Chromatin looping assays (3C/ChIA-PET), enhancer knockout (CRISPR), ChIP for AR, FOXA1, and p300, cell growth and migration assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chromatin looping with CRISPR knockout validation, single study\",\n      \"pmids\": [\"31405024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A common TMPRSS2 variant rs12329760 (p.V160M) reduces TMPRSS2 catalytic activity and is less able to support SARS-CoV-2 spike-mediated entry into cells; homozygous carriers have significantly decreased risk of severe COVID-19.\",\n      \"method\": \"SARS-CoV-2 pseudovirus entry assay in HEK293 cells co-transfected with ACE2 and wild-type or V160M TMPRSS2, epidemiological association in 2,244 ICU patients\",\n      \"journal\": \"Current research in translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro assay with clinical genetic association, single study\",\n      \"pmids\": [\"35104687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An RNA G-quadruplex (RG4) structure within TMPRSS2 mRNA inhibits TMPRSS2 translation; G4-specific stabilizers attenuate SARS-CoV-2 infection in pseudovirus systems and mouse models; TMPRSS2 protein is increased in COVID-19 patient lungs.\",\n      \"method\": \"Bioinformatics identification of RG4, biochemical and biophysical RG4 characterization, in vitro translation assays, pseudovirus infection, mouse model with G4 stabilizers, COVID-19 patient lung protein analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical RG4 characterization plus functional translation and infection assays, in vivo validation\",\n      \"pmids\": [\"35301316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Antithrombin (AT), an endogenous serine protease inhibitor, binds and inhibits TMPRSS2 (demonstrated by molecular docking and enzyme activity assays), blocking spike-mediated entry of multiple coronaviruses and suppressing authentic SARS-CoV-2 lung cell infection; heparin/fondaparinux activation of AT increases its anti-TMPRSS2 activity.\",\n      \"method\": \"Molecular docking, enzyme activity assays, pseudovirus entry assays for multiple coronavirus spikes, authentic SARS-CoV-2 lung cell infection assay\",\n      \"journal\": \"Journal of medical virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzyme activity assays combined with functional viral entry assays, single study\",\n      \"pmids\": [\"36056630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-98-5p directly targets TMPRSS2 mRNA and was mechanistically validated as a regulator of TMPRSS2 protein expression in human lung and umbilical vein endothelial cells.\",\n      \"method\": \"Bioinformatic miRNA target prediction, functional validation of miR-98-5p regulation of TMPRSS2 in two human endothelial cell lines\",\n      \"journal\": \"Biomedicines\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single study, functional validation not extensively detailed in abstract\",\n      \"pmids\": [\"33143053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Androgens regulate TMPRSS2 expression in lung epithelial cells via androgen receptor; antiandrogen enzalutamide reduces TMPRSS2 levels in human lung cells and mouse lung, significantly reducing SARS-CoV-2 entry and infection.\",\n      \"method\": \"Quantitative gene expression analysis in lung cell lines and mouse lung, antiandrogen treatment, SARS-CoV-2 infection assays in lung cells with and without enzalutamide\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct AR-TMPRSS2 transcriptional link shown with functional viral entry consequence, single study\",\n      \"pmids\": [\"34210968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PM2.5 activates AhR, which translocates to the nucleus and directly binds the TMPRSS2 promoter, upregulating TMPRSS2 and downstream IL18 expression to promote lung cancer progression; TMPRSS2 depletion suppressed anchorage-independent growth and xenograft tumor growth.\",\n      \"method\": \"AhR nuclear translocation assays, ChIP showing AhR binding to TMPRSS2 promoter, TMPRSS2 knockdown in lung cancer cells, anchorage-independent growth assays, xenograft mouse model\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP evidence for direct AhR-TMPRSS2 promoter interaction with functional KD validation in vivo\",\n      \"pmids\": [\"36975376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TMPRSS2/ERG gene fusion is expressed in prostate cancer stem cells with monoallelic regulation; TMPRSS2 transcription is subject to tight monoallelic control throughout the prostate epithelial hierarchy in both normal and tumor tissues, relaxed during differentiation.\",\n      \"method\": \"FISH for fusion gene in sorted prostate cancer stem cells, allele-specific expression analysis, single cell clonal analysis of asymmetric division\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — allele-specific expression and stem cell sorting with functional characterization, single study\",\n      \"pmids\": [\"23535644\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TMPRSS2 is a type II transmembrane serine protease that is autocatalytically activated from its zymogen form and functions at the cell surface to proteolytically prime viral spike proteins (including SARS-CoV-2, influenza hemagglutinin, and HCoV-HKU1) for membrane fusion and viral entry; in prostate cancer, its androgen-regulated promoter is recurrently fused to ETS oncogene coding sequences (most commonly ERG), driving androgen-dependent ETS overexpression and invasion, while the TMPRSS2-ERG fusion protein recruits BAF chromatin remodeling complexes and is post-translationally regulated by EZH2-mediated methylation at K362, with endogenous inhibitors including HAI-2, alpha-1 antitrypsin, and antithrombin modulating its proteolytic activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TMPRSS2 is a type II transmembrane serine protease, expressed under androgen receptor control predominantly in prostate and lung epithelia, that functions at the cell surface to proteolytically activate viral glycoproteins and endogenous substrates. Its serine protease domain cleaves the spike proteins of SARS-CoV-2, SARS-CoV, influenza hemagglutinin, and HCV entry factors, enabling plasma-membrane-route viral fusion; TMPRSS2 knockout in mice strongly reduces SARS-CoV-2 replication in the respiratory tract, and small-molecule inhibitors (camostat, nafamostat, N-0385) block this entry pathway [PMID:32142651, PMID:36243815, PMID:35344983]. Beyond its catalytic role, TMPRSS2 serves as a proteinaceous entry receptor for HCoV-HKU1, binding the viral RBD through its catalytic groove even when proteolytically inactive, with structural rearrangements upon zymogen activation dramatically increasing binding affinity [PMID:37879362, PMID:38964326]. In prostate cancer, recurrent chromosomal rearrangements fuse the androgen-responsive TMPRSS2 promoter to ETS family oncogenes (most commonly ERG), driving androgen-dependent ERG overexpression that recruits BAF chromatin-remodeling complexes genome-wide and promotes invasion through the plasminogen activation pathway [PMID:16254181, PMID:30078722, PMID:18283340].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing TMPRSS2 as a novel transmembrane serine protease with androgen-regulated expression in prostate epithelium defined the gene's identity, domain architecture, and hormonal control before any functional role was known.\",\n      \"evidence\": \"cDNA microarray of androgen-treated prostate cancer cells, Northern blot, in situ hybridization\",\n      \"pmids\": [\"10485450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous substrate identified\", \"Catalytic activity not directly demonstrated\", \"Expression in non-prostate tissues not systematically surveyed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that recurrent TMPRSS2-ETS gene fusions place oncogenic ETS transcription factors under androgen-responsive TMPRSS2 promoter control established a new paradigm for epithelial cancer-associated gene fusions and explained the frequent ETS overexpression in prostate cancer.\",\n      \"evidence\": \"Outlier expression bioinformatics, RT-PCR, FISH on prostate cancer tissues\",\n      \"pmids\": [\"16254181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which fusion drives transformation not yet defined\", \"Frequency across ethnic groups unknown\", \"Cooperating oncogenic events not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that the TMPRSS2-ERG fusion product drives prostate epithelial cell invasion through the plasminogen activation pathway resolved how ETS overexpression contributes to prostate cancer aggressiveness.\",\n      \"evidence\": \"Transgenic mouse model, ERG knockdown in VCaP cells, invasion assays, transcriptional profiling\",\n      \"pmids\": [\"18283340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERG suffices for full transformation or requires cooperating events\", \"Direct ERG transcriptional targets mediating invasion incompletely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing that androgen treatment can induce TMPRSS2-ERG chromosomal fusions in non-malignant prostate cells addressed whether the fusion is an initiating event or consequence of malignancy, establishing that androgen-driven spatial proximity of the TMPRSS2 and ERG loci enables rearrangement prior to transformation.\",\n      \"evidence\": \"RT-PCR for fusion transcripts after androgen treatment, FISH for gene proximity\",\n      \"pmids\": [\"20947519\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Frequency of de novo fusion induction in normal cells very low\", \"DNA repair defect requirement not tested\", \"Not independently replicated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of the upstream androgen-responsive enhancer with ARE and GATA2 sites, plus a functional SNP (rs8134378) modulating AR binding, provided the cis-regulatory architecture explaining how androgens control TMPRSS2 transcription and how genetic variation affects expression levels.\",\n      \"evidence\": \"BAC reporters, DNase I footprinting, ARE mutagenesis, AR binding assays, SNP functional analysis\",\n      \"pmids\": [\"24109594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of additional distal enhancers not fully mapped\", \"Tissue-specific enhancer usage (prostate vs. lung) not compared\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that TMPRSS2 proteolytic activity at the cell surface activates HCV infection and cleaves influenza HA established TMPRSS2 as a broadly relevant host protease for respiratory and hepatotropic viruses beyond coronaviruses.\",\n      \"evidence\": \"Stable wild-type vs. catalytic mutant expression, HCV infection assays, HA cleavage assays, pseudovirus entry with cathepsin inhibition\",\n      \"pmids\": [\"25203900\", \"26379044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance for HCV not demonstrated\", \"Full range of viral substrates not surveyed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that clinical HCoV-OC43 and HCoV-HKU1 isolates preferentially use TMPRSS2 rather than cathepsins for spike priming established that the TMPRSS2-dependent plasma membrane entry route is the physiologically dominant pathway for human coronaviruses in airway epithelia.\",\n      \"evidence\": \"Infection assays with clinical vs. culture-adapted strains, pharmacological pathway dissection, air-liquid interface cultures\",\n      \"pmids\": [\"29217279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genetic knockout confirmation not performed\", \"Whether other TTSPs can compensate not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of FOXO1 as a direct binding partner and functional inhibitor of ERG activity, with in vivo validation that Foxo1 loss cooperates with ERG to drive prostate neoplasia, revealed a tumor-suppressive checkpoint on TMPRSS2-ERG oncogenic signaling.\",\n      \"evidence\": \"Co-IP, reporter assays, siRNA knockdown, invasion assays, genetically engineered mouse model\",\n      \"pmids\": [\"28986382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FOXO1-ERG interaction is regulated by upstream signals incompletely defined\", \"Relevance in human prostate cancer progression not directly tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that the TMPRSS2-ERG fusion protein directly recruits BAF (SWI/SNF) chromatin-remodeling complexes to ETS motifs genome-wide resolved the chromatin-level mechanism by which ERG overexpression reprograms the prostate cancer epigenome.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP-seq, prostate organoid model with BAF perturbation\",\n      \"pmids\": [\"30078722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which BAF subunit directly contacts ERG not identified\", \"Whether BAF retargeting is reversible upon ERG depletion not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The landmark demonstration that SARS-CoV-2 requires TMPRSS2 for spike priming and cell entry—blockable by camostat—established TMPRSS2 as a therapeutic target for COVID-19 and explained the virus's tropism for TMPRSS2-expressing airway cells.\",\n      \"evidence\": \"Pseudovirus and authentic virus infection, TMPRSS2-expressing vs. non-expressing cells, camostat inhibition\",\n      \"pmids\": [\"32142651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of camostat not yet demonstrated in this study\", \"Relative contribution vs. cathepsin pathway in different tissues unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of endogenous inhibitors alpha-1 antitrypsin and HAI-2 as direct TMPRSS2-binding inhibitors that suppress both viral entry and cancer cell invasion, respectively, revealed physiological regulatory mechanisms controlling TMPRSS2 proteolytic activity in airway and prostate contexts.\",\n      \"evidence\": \"Co-IP/MS for HAI-2, bronchoalveolar lavage screen for α1AT, enzyme activity assays, pseudovirus/authentic virus infection, xenograft models\",\n      \"pmids\": [\"33741941\", \"32778768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether α1AT deficiency predisposes to severe COVID-19 not causally demonstrated\", \"Stoichiometry of HAI-2–TMPRSS2 complex not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that EZH2 methylates the TMPRSS2-ERG fusion product at K362, enhancing ERG DNA binding and transcriptional activity downstream of PTEN loss/AKT signaling, integrated the TMPRSS2-ERG axis with PI3K and Polycomb pathways in prostate cancer progression.\",\n      \"evidence\": \"In vitro methylation assays, K362 mutagenesis, ChIP-seq, Co-IP, genetically engineered mouse model\",\n      \"pmids\": [\"34230470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether K362 methylation is targetable therapeutically not tested\", \"Dynamics of methylation during disease progression unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The crystal structure of TMPRSS2 with nafamostat revealed the substrate-binding pocket architecture and enabled structure-guided inhibitor optimization, while in vivo knockout and inhibitor studies (N-0385) confirmed TMPRSS2 is essential for SARS-CoV-2 replication in mouse airways across multiple variants including Omicron.\",\n      \"evidence\": \"X-ray crystallography at 1.95 Å, in vitro enzymatic assays, TMPRSS2-KO mice with Beta/Omicron infection, K18-hACE2 mouse model with N-0385\",\n      \"pmids\": [\"35676539\", \"36243815\", \"35344983\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No human clinical trial data for TMPRSS2-specific inhibitors\", \"Whether compensatory proteases emerge under TMPRSS2 blockade in vivo not addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that SARS-CoV-2 Omicron shifts away from TMPRSS2-dependent plasma membrane entry toward cathepsin-dependent endosomal entry explained its altered cell tropism and reduced pathogenicity in the lower respiratory tract.\",\n      \"evidence\": \"Pseudovirus entry in cells with differential TMPRSS2, gene deletion, drug inhibitors, airway organoids\",\n      \"pmids\": [\"35104837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether tropism shift is solely due to spike S1/S2 cleavage efficiency or involves other determinants\", \"Long-term evolutionary trajectory of TMPRSS2 dependence unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The discovery that TMPRSS2 functions as a bona fide entry receptor for HCoV-HKU1—binding the viral RBD with high affinity even when catalytically dead—fundamentally expanded TMPRSS2's role from protease to receptor, revealing a dual protease-receptor function.\",\n      \"evidence\": \"Pseudovirus and authentic HKU1 infection, catalytic-dead TMPRSS2 mutants, Kd measurements, nanobody inhibition, primary bronchial cell infection\",\n      \"pmids\": [\"37879362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other TTSPs can substitute as HKU1 receptors not tested\", \"Structural basis not yet resolved at this point\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Crystal and cryo-EM structures of HKU1 RBD–TMPRSS2 complexes revealed that HKU1 recognizes the TMPRSS2 catalytic groove through an insertion subdomain, that zymogen-to-active conformational changes dramatically increase binding affinity, and that sialoglycan binding to HKU1 NTD allosterically promotes RBD opening for TMPRSS2 engagement—providing a complete structural model of synergistic dual-receptor usage.\",\n      \"evidence\": \"Crystal structures of HKU1-RBD:TMPRSS2 and zymogen/active TMPRSS2 with nanobody, cryo-EM of HKU1 spike in multiple states, mutagenesis, cross-species tropism analysis\",\n      \"pmids\": [\"38964326\", \"38964329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether therapeutic antibodies blocking the HKU1–TMPRSS2 interface are viable not tested\", \"Structural basis for TMPRSS2's catalytic cleavage of HKU1 spike not resolved separately from receptor binding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full endogenous substrate repertoire of TMPRSS2 in normal physiology, whether TMPRSS2 inhibition is clinically effective against respiratory viral infections in humans, and the structural determinants governing selectivity between TMPRSS2's protease versus receptor functions for different viruses.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No endogenous physiological substrate comprehensively validated in vivo\", \"No completed human clinical trial demonstrating efficacy of TMPRSS2-specific inhibitors\", \"Mechanism by which TMPRSS2 loss is tolerated in knockout mice (no overt phenotype) unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 4, 5, 15, 16, 19, 20]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [11, 12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 0, 19, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 3, 6, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 5, 16, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 29, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ACE2\",\n      \"HAI-2\",\n      \"ERG\",\n      \"SERPINA1\",\n      \"FOXO1\",\n      \"EZH2\",\n      \"SMARCA4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}